Primary bioavailability parameters of loratadine in CYP2D6 extensive metabolizers

被引：0
|
作者：
Kunicki, PK
Gutkowski, P
机构：
[1] Natl Inst Cardiol, Dept Clin Biochem, Clin Pharmacol Unit, Warsaw, Poland
[2] TRIAL Clin Res Ctr, Warsaw, Poland
来源：
THERAPEUTIC DRUG MONITORING | 2003年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
156
引用
收藏
页码：525 / 525
页数：1
相关论文
共 50 条
  • [41] Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers
    de Leon, J
    Dinsmore, L
    Wedlund, P
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) : 420 - 421
  • [42] Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
    Loghin, Corina
    Haber, Harry
    Beasley, Charles M., Jr.
    Kothare, Prajakti A.
    Kauffman, Lynnette
    April, John
    Jin, Ling
    Allen, Albert J.
    Mitchell, Malcolm I.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 549 - 560
  • [43] Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
    Desta, Z
    Kerbusch, T
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (01) : 10 - 20
  • [44] CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
    Molden, Espen
    Jukic, Marin M.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [45] Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects
    Yin, OQP
    Shi, XJ
    Tomlinson, B
    Chow, MSS
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (09) : 1283 - 1287
  • [46] Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug
    Li, Qian
    Wu, Yue-E
    Wang, Kai
    Shi, Hai-Yan
    Zhou, Yue
    Zheng, Yi
    Hao, Guo-Xiang
    Yang, Yi-Lei
    Su, Le-Qun
    Wang, Wen-Qi
    Yang, Xin-Mei
    Zhao, Wei
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [47] Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline
    Davies, Benjamin J.
    Herbert, Megan K.
    Coller, Janet K.
    Somogyi, Andrew A.
    Milne, Robert W.
    Sallustio, Benedetta C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (03) : 347 - 354
  • [48] Identifying CYP2C19 and CYP2D6 poor metabolizers from TDM data
    Molden, E.
    PHARMACOPSYCHIATRY, 2024, 57 (02) : 86 - 86
  • [49] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [50] Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
    Chung, Woo Kyung
    Hwang, Inyoung
    Kim, Byungwook
    Jung, Jihyun
    Yu, Kyung-Sang
    Jang, In-Jin
    Oh, Jaeseong
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 512 - 523
12345